Dysregulation of Ca 2+ homeostasis in Alzheimer's disease: Role in acetylcholinesterase production and AMPA receptor internalization

Neurodegenerative Diseases

Volumn 10, Issue 1-4, 2012, Pages 76-79

  Small, David H ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Acetylcholinesterase; AMPA receptor; Amyloid; Calcium; Synaptic scaling

Indexed keywords

ACETYLCHOLINESTERASE; AMPA RECEPTOR; AMYLOID BETA PROTEIN; CALCIUM ION; CALCIUM;

ALZHEIMER DISEASE; ARTICLE; ENZYME SYNTHESIS; HOMEOSTASIS; HUMAN; NERVE CELL EXCITABILITY; PRIORITY JOURNAL; SYNAPSE; ANIMAL; DRUG EFFECT; METABOLISM; NERVE CELL; PHYSIOLOGY;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CALCIUM; HOMEOSTASIS; HUMANS; NEURONS; RECEPTORS, AMPA; SYNAPSES;

EID: 84860219733     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000333126     Document Type: Article

References (30)

1. Small DH, Mok SS, Bornstein JC: Alzheimer's disease and A3β toxicity: from top to bottom. Nat Rev Neurosci 2001; 2: 595-598.
2. Subasinghe S, Unabia S, Barrow CJ, Mok SS, Aguilar MI, Small DH: Cholesterol is necessary both for the toxic effect of A3β peptides on vascular smooth muscle cells and for A3β binding to vascular smooth muscle cell membranes. J Neurochem 2003; 84: 471-479.
3. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P: Regulation of NMDA receptor trafficking by amyloid-3β . Nat Neurosci 2005; 8: 1051-1058.
4. Coulson EJ: Does the p75 neurotrophin receptor mediate A3β -induced toxicity in Alzheimer's disease? J Neurochem 2006; 98: 654-660.
5. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM: RAGE and amyloid-3β peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382: 685-691.
6. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB:3β 42-amyloid(1-42) binds to/α /e 7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 2000; 275: 5626-5632.
7. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE:3β 42-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992; 12: 376-389.
8. Gibson GE, Shi Q: A mitocentric view of Alzheimer's disease suggests multi-faceted treatments. J Alzheimers Dis 2010; 20(suppl 2):S591-S607.
9. Ferretti MT, Cuello AC: Does a pro-inflammatory process precede Alzheimer's disease and mild cognitive impairment? Curr Alzheimer Res 2011; 8: 164-174.
10. Jo J, Whitcomb DJ, Olsen KM, Kerrigan TL, Lo SC, Bru-Mercier G, Dickinson B, Scullion S, Sheng M, Collingridge G, Cho K: A3β (1- 42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-33β . Nat Neurosci 2011; 14: 545-547.
11. Liu T, Perry G, Chan HW, Verdile G, Martins RN, Smith MA, Atwood CS: Amyloid-3β -induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression. J Neurochem 2004; 88: 554-563.
12. Yu JT, Chang RC, Tan L: Calcium dysregulation in Alzheimer's disease: from mechanisms to therapeutic opportunities. Prog Neurobiol 2009; 89: 240-255.
13. Kullmann DM, Lamsa KP: Long-term synaptic plasticity in hippocampal interneurons. Nat Rev Neurosci 2007; 8: 687-699.
14. Mattson MP, LaFerla FM, Chan SL, Leissring MA, Shepel PN, Geiger JD: Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends Neurosci 2000; 23: 222-229.
15. 2+elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci 2010; 30: 11938-11950.
16. Arispe N, Rojas E, Pollard HB: Alzheimer disease amyloidβ protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci USA 1993; 90: 567-571.
17. Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, Glabe CG: Permeabilization of lipid bilayers is a common conformation- dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 2004; 279: 46363-46366.
18. Liu SJ, Gasperini R, Foa L, Small DH: Amyloid-3β decreases cell-surface AMPA receptors by increasing intracellular calcium and phosphorylation of GluR2. J Alzheimers Dis 2010; 21: 655-666.
19. Small DH, Gasperini R, Vincent AJ, Hung AC, Foa L: The role of A3β -induced calcium dysregulation in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 2009; 16: 225-233.
20. Kuchibhotla KV, Goldman ST, Lattarulo CR, Wu HY, Hyman BT, Bacskai BJ: A3β plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 2008; 59: 214-225.
21. Sáez-Valero J, Sberna G, McLean CA, Small DH: Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease. J Neurochem 1999; 72: 1600-1608.
22. Sberna G, Sáez-Valero J, Li QX, Czech C, Beyreuther K, Masters CL, McLean CA, Small DH: Acetylcholinesterase is increased in the brains of transgenic mice expressing the C-terminal fragment (CT100) of the3β- amyloid protein precursor of Alzheimer's disease. J Neurochem 1998; 71: 723-731.
23. Fodero LR, Sáez-Valero J, McLean CA, Martins RN, Beyreuther K, Masters CL, Robertson TA, Small DH: Altered glycosylation of acetylcholinesterase in APP (SW) Tg2576 transgenic mice occurs prior to amyloid plaque deposition. J Neurochem 2002; 81: 441-448.
24. Sáez-Valero J, de Ceballos ML, Small DH, de Felipe C: Changes in molecular isoform distribution of acetylcholinesterase in rat cortex and cerebrospinal fluid after intracerebroventricular administration of amyloidβ -peptide. Neurosci Lett 2002; 325: 199-202.
25. Sberna G, Sáez-Valero J, Beyreuther K, Masters CL, Small DH: The amyloidβ -protein of Alzheimer's disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma P19 cells. J Neurochem 1997; 69: 1177-1184.
26. Henley JM, Barker EA, Glebov OO: Routes, destinations and delays: recent advances in AMPA receptor trafficking. Trends Neurosci 2011; 34: 258-268.
27. Carter TL, Rissman RA, Mishizen-Eberz AJ, Wolfe BB, Hamilton RL, Gandy S, Armstrong DM: Differential preservation of AMPA receptor subunits in the hippocampi of Alzheimer's disease patients according to Braak stage. Exp Neurol 2004; 187: 299-309.
28. Cha JH, Farrell LA, Ahmed SF, Frey A, Hsiao-Ashe KK, Young AB, Penney JB, Locascio JJ, Hyman BT, Irizarry MC: Glutamate receptor dysregulation in the hippocampus of transgenic mice carrying mutated human amyloid precursor protein. Neurobiol Dis 2001; 8: 90-102.
29. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R: AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 2006; 52: 831-843.
30. Small DH: Network dysfunction in Alzheimer's disease: does synaptic scaling drive disease progression? Trends Mol Med 2008; 14: 103-108.